Two impressive studies in lung cancer and another in breast cancer made Sunday a stellar day for AstraZeneca at the ASCO congress. Three of the group’s top cancer drugs were on display – EGFR ...
Bill Lundberg, Merus' president and CEO. For the second year running, data at ASCO on Merus' bispecific antibody petosemtamab in head and neck cancer has drawn the eye, as the company talks up its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback